DDR1 and colorectal carcinoma: In the case of CRC, recent studies have shown that nilotinib, a specific inhibitor of DDR1 phosphorylation, strongly reduced DDR1-mediated CRC cell invasion and metastasis in mouse models (Jeitany et al., 2018), and that the use of antibody-drug conjugates targeting DDR1 exhibits antitumor effects in a mouse model of CRC (Tao et al., 2019).